| Date Filed | Type | Description |
| 08/21/2023 |
4
| Smith Karen L. (Director) has filed a Form 4 on Aurinia Pharmaceuticals Inc.|
Txns:
| Granted 17,913 restricted stock units
@ $0
Granted 28,959 options to buy
@ $9.49, valued at
$274.8k
|
|
| 08/21/2023 |
3
| Smith Karen L. (Director) has filed a Form 3 on Aurinia Pharmaceuticals Inc. |
| 06/05/2023 |
4
| Smith Karen L. (Director) has filed a Form 4 on SANGAMO THERAPEUTICS, INC|
Txns:
| Granted 13,900 shares
@ $0
Granted 27,750 options to buy
@ $1.11, valued at
$30.8k
|
|
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/27/2022 |
4/A
| Smith Karen L. (Chief Medical Officer) has filed a Form 4 on Cortexyme, Inc.|
Txns:
| Granted 170,354 shares
@ $0 |
|
| 05/26/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/23/2022 |
4
| Smith Karen L. (Chief Medical Officer) has filed a Form 4 on Cortexyme, Inc.|
Txns:
| Granted 24,336 shares
@ $0
Granted 151,799 options to buy
@ $0.55, valued at
$83.5k
Granted 1,365,449 options to buy
@ $2.98, valued at
$4.1M
|
|
| 05/23/2022 |
3
| Smith Karen L. (Chief Medical Officer) has filed a Form 3 on Cortexyme, Inc. |
| 05/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/17/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 03/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/22/2021 |
4
| Smith Karen L. (Director) has filed a Form 4 on ACCELERON PHARMA INC|
Txns:
| Unknown transaction of 1,622 shares
@ $0
Disposed/sold 10,000 options to buy
@ $35.34, valued at
$353.4k
Disposed/sold 1,875 options to buy
@ $40.61, valued at
$76.1k
Disposed/sold 3,750 options to buy
@ $41.64, valued at
$156.2k
Disposed/sold 4,085 options to buy
@ $52.99, valued at
$216.5k
Disposed/sold 3,222 options to buy
@ $115.53, valued at
$372.2k
|
|
| 06/14/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/11/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/01/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/26/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/15/2020 |
4
| Smith Karen L. (Director) has filed a Form 4 on ANTARES PHARMA, INC.|
Txns:
| Granted 30,220 shares
@ $2.73, valued at
$82.5k
Granted 58,246 options to buy
@ $2.73, valued at
$159k
|
|
| 06/03/2020 |
4/A
| Smith Karen L. (Director) has filed a Form 4 on SANGAMO THERAPEUTICS, INC|
Txns:
| Granted 10,000 shares
@ $0
Granted 20,000 options to buy
@ $10.46, valued at
$209.2k
|
|
| 05/28/2020 |
3
| Smith Karen L. (EVP, Chief Medical Officer) has filed a Form 3 on Emergent BioSolutions Inc. |
| 05/20/2020 |
4
| Smith Karen L. (Director) has filed a Form 4 on SANGAMO THERAPEUTICS, INC|
Txns:
| Granted 2,500 shares
@ $0
Granted 15,000 options to buy
@ $10.46, valued at
$156.9k
|
|
| 01/24/2020 |
4
| Smith Karen L. (Director) has filed a Form 4 on ACCELERON PHARMA INC|
Txns:
| Granted 1,377 shares
@ $0
Granted 8,185 options to buy
@ $52.99, valued at
$433.7k
|
|
| 06/14/2019 |
4
| Smith Karen L. (Director) has filed a Form 4 on ANTARES PHARMA, INC.|
Txns:
| Granted 23,973 shares
@ $2.92, valued at
$70k
Granted 46,729 options to buy
@ $2.92, valued at
$136.4k
|
|
| 06/12/2019 |
4
| Smith Karen L. (Director) has filed a Form 4 on SANGAMO THERAPEUTICS, INC|
Txns:
| Granted 2,500 shares
@ $0
Granted 15,000 options to buy
@ $9.38, valued at
$140.7k
|
|
| 03/05/2019 |
4
| Smith Karen L. (Director) has filed a Form 4 on ANTARES PHARMA, INC.|
Txns:
| Granted 20,000 options to buy
@ $3.72, valued at
$74.4k
|
|
| 03/05/2019 |
3
| Smith Karen L. (Director) has filed a Form 3 on ANTARES PHARMA, INC. |
| 01/29/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/28/2018 |
4
| Smith Karen L. (Director) has filed a Form 4 on SANGAMO THERAPEUTICS, INC|
Txns:
| Granted 5,000 shares
@ $0
Granted 30,000 options to buy
@ $15.65, valued at
$469.5k
|
|
| 06/28/2018 |
3
| Smith Karen L. (Director) has filed a Form 3 on SANGAMO THERAPEUTICS, INC |
| 03/07/2018 |
4
| Smith Karen L. (EVP, R&D and CMO) has filed a Form 4 on Jazz Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 648 shares
@ $143.39, valued at
$92.9k
|
|
| 03/05/2018 |
4
| Smith Karen L. (Director) has filed a Form 4 on ACCELERON PHARMA INC|
Txns:
| Granted 312 shares
@ $0
Granted 1,875 options to buy
@ $40.61, valued at
$76.1k
|
|
|